Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3032 in overweight or obesity
NCT07170319Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3032 in obesity (10 cohorts), sponsored by Innovent Biologics. Primary endpoints: Serious Adverse Events at 43 days and Adverse Events at 43 days. Started Sep 2025; status: active, not recruiting.
02
Drugs
IBI3032
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07170319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170319.